Four non-executive directors appointed to the Board of the Medicines and Health Products Regulatory Agency
Dr Junaid Bajwa, Professor Graham Cooke, Dr Paul Goldsmith and Raj Long have been appointed non-executive directors to the board of directors of the Medicines and Health Products Regulatory Agency (MHRA) for three years.
In addition, Haider Husain was appointed associate non-executive director without voting rights in order to enrich the board of directors.
Their terms will come into effect on September 1, 2021 to replace Dr Barbara Bannister MBE, Professor Bruce Campbell, Anne-Toni Rodgers and Professor David Webb CBE whose terms all expired on August 31, 2021.
Mandy Calvert, Mercy Jeyasingham MBE and Michael Whitehouse OBE will also continue to serve as non-executive directors on the MHRA board until the end of their term in 2023.
I am pleased to report that after a comprehensive search and selection process, we have been able to nominate such talented non-executive directors to the MHRA Board of Directors. Their appointment brings a wealth of diverse experience and expertise that will add considerable value to the Agency’s strategic leadership.
I would also like to thank our outgoing non-executive directors for their hard work, commitment and wise advice during a difficult and high-profile period in the history of the Agency.
Notes to Editors
Dr Junaid Bajwa has extensive experience in global digital health from a software and pharmaceutical perspective, combined with his continued clinical, academic and non-executive experience across the globe.
Junaid is Chief Scientific Officer at Microsoft Research, Practicing General Practitioner in London, Non-Executive Director of University College London Hospitals NHS Foundation Trust, Non-Executive Director of Nahdi Medical Corporation in Saudi Arabia, and Visiting Fellow at Harvard School of Public Health in the USA. He was previously Executive Director of the Digital Center of Excellence at global pharmaceutical company Merck Sharp & Dohme, where he helped shape the company’s global digital strategy and then led the academic and technology partnerships to implement it.
Professor Graham Cooke has extensive experience in international clinical research, innovative clinical trial design, World Health Organization (WHO) committees and expert groups.
Graham is the NIHR Professor of Infectious Diseases at Imperial College London and leads translational infection research at the NIHR Biomedical Research Center with a particular interest in precision drugs and diagnostics. He was the principal investigator of the REACT home testing COVID-19 study with over 3 million participants and was involved in several other COVID-19 studies and expert panels. Graham’s international experience also includes chairmanship of the WHO Committee on the Selection and Use of Essential Medicines, which has led to globally recognized recommendations on the use of innovative therapies and antibiotics. Graham’s experience also includes being a founding principal investigator of the National Health Informatics Collaborative, collecting secondary care data to complement our Clinical Practice Research Datalink (CPRD) primary care data and was a facilitator of ‘a group of clinical experts for the investigation of infected blood.
Dr Paul Goldsmith has extensive experience in clinical, drug development, digital health and governance, while also being a serial innovator who co-founded 4 healthcare companies.
He has extensive experience in frontline clinical medicine as a consultant neurologist and has held positions in the NHS, Vanguard and Senate clinical networks. He is also President, Chief Innovation Officer and Co-Founder of Closed Loop Medicine Limited, as well as a Board Member of MDU Ltd and MDU Investments Ltd, and a Director of the Big Tent Foundation. Paul’s start-ups have involved disease modeling, drug development, delivery of automated digital therapies, online cognitive behavioral therapy, and drug optimization by integrating the use of diagnostics, drugs and therapy. digital technologies. He holds a doctorate in developmental biology and has a particular interest in the application of knowledge from evolutionary neuroscience to problems of modern life.
Raj Long has considerable experience as a senior international regulatory executive in the pharmaceutical industry, combined with strategic experience as an advisor to the Ministry of Health and Social Affairs, European Union, Gates Foundation and the World Health Organization (WHO).
Raj is currently Deputy Director of Safety and Pharmacovigilance at the Gates Foundation and also supports the WHO COVID-19 Vaccine Manufacturing Working Group. Prior to that, Raj served as an advisory advisor to the WHO Chief Scientist, as well as a WHO co-lead on the COVAX working group on the manufacture of COVID-19 vaccines and supporting other committees of the WHO, Vice-Chairman of the World Dementia Council and has provided advice to numerous expert groups and government initiatives such as the G7 Global Action Against Dementia initiative and the Accelerated Access Review with NHS England. During his executive career, Raj has held very senior international regulatory positions with responsibility for licensing innovative medicines at global pharmaceutical companies such as Bristol Myers Squibb, Novartis and GE Healthcare.
Haider Husain is an experienced international business leader in the healthcare information technology field with a solid background in technology and experience working in partnership, combined with his work as a panel chair for the British Standards Institute (BSI) and non-executive experience in the NHS.
Haider is COO of an international health technology consultancy firm called Healthinnova Limited, non-executive director of Milton Keynes University Hospital NHS Foundation Trust and chair of the Committee for the Safe and Efficient Use of AI in health care at the British Standards Institute. Previously, Haider was Managing Director of Caradigm’s European Population Health Management business and worked for other international companies such as Microsoft, GE Healthcare and Logica.
- These appointments of non-executive directors are made by ministers in accordance with the Cabinet Office Governance Code for Public Appointments. The regulation of public appointments in relation to the requirements of this Code is carried out by the Public Appointments Commissioner.
- Associate non-executive directors are appointed by the chairman of the MHRA board to provide additional and in-depth experience to enable the board to fulfill its responsibilities, but they have no voting rights.
- Appointments are made on merit and political activity has played no role in the decision-making process. However, in accordance with the Code, the political activity of appointees (if any declared) must be made public.
- The appointment will involve a time commitment of 2 to 3 days per month. Annual compensation for the post will be £ 7,883 for required preparation and attendance at board meetings and board committee meetings.
- More information on the work of the Agency Board can be found on the MHRA Governance page